Scientific Poster Session II: Students Research-in-Progress

Students Research in Progress
  Sunday, November 12, 2023
  12:45 PM–02:15 PM

Abstract

Montana A. Panec, Ryan R. Reeves, Douglas M. Humber; UC San Diego Health, San Diego, CA

Title: Evaluation of bleeding complications associated with left atrial appendage occlusion (LAAO) procedure in patients receiving long-term anti-platelet therapy

Introduction: Individuals with atrial fibrillation can suffer from a cardioembolic stroke originating from the left atrial appendage (LAA). LAAO devices are implanted with the intent to reduce the risk of thromboembolism in patients with non-valvular atrial fibrillation. However, there is uncertainty regarding best practices for LAAO pre-procedural management of antiplatelet therapy. Given the limited and conflicting data surrounding uninterrupted pre-procedural antiplatelet therapy, this study aims to gain insight into the safety of antiplatelet therapy in individuals undergoing LAAO procedures, specifically the placement of either the Watchman^TM (Boston Scientific) or Amplatzer^TM Amulet^TM (Abbott Medical) devices.

Research Question or Hypothesis: Individuals treated with pre-procedural antiplatelet therapy will experience increased bleeding and a lower incidence of thrombotic complications compared to those not on antiplatelet therapy.

Study Design: A single-center, retrospective cohort study will be conducted for LAAO procedures performed between March 2020 to March 2022 at UC San Diego Health.

Methods: The primary endpoint is the composite incidence of bleeding, as defined by the Valve Academic Research Consortium (VARC) definition, and thrombotic events (MI, stroke, and death) during the first 48 hours following device implantation. Secondary endpoints include length of hospital admission and readmission within 6 months. Odds ratio will be used to compare the primary endpoint between the two cohorts. Descriptive statistics will be reported. A post-hoc analysis and multi-variable logistic regression will be conducted to compare the primary outcome between dual antiplatelet therapy (DAPT), single antiplatelet therapy (SAPT) with a P2Y12 inhibitor alone, SAPT with aspirin alone, and no antiplatelet therapy.

Results: Results will be released following data collection and statistical analysis.

Conclusion: Conclusion is pending results.

Presenting Author

Montana Panec BS
University of California, San Diego

Authors

Doug Humber PharmD
UC San Diego Health

Ryan Reeves MD
UC San Diego Health